Get the Stockscreener App
3.18
2.15%
-0.07
Pre-market:
3.09
-0.09
-2.83%
Cyclerion Therapeutics Inc stock is traded at $3.18, with a volume of 36,993.
It is down -2.15% in the last 24 hours and up +1.92% over the past month.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.
See More
Previous Close:
$3.25
Open:
$3.31
24h Volume:
36,993
Relative Volume:
0.01
Market Cap:
$13.77M
Revenue:
$1.99M
Net Income/Loss:
$-5.28M
P/E Ratio:
-2.3166
EPS:
-1.3727
Net Cash Flow:
$-3.59M
1W Performance:
+5.65%
1M Performance:
+1.92%
6M Performance:
+98.75%
1Y Performance:
+2.13%
1-Day Range:
$3.18
$3.40
1-Week Range:
$2.96
$3.40
52-Week Range:
$1.0266
$8.48
Cyclerion Therapeutics Inc Stock (CYCN) Company Profile
Name
Cyclerion Therapeutics Inc
Sector
Industry
Phone
617-621-7722
Address
301 BINNEY STREET, CAMBRIDGE, MA
Compare CYCN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYCN
Cyclerion Therapeutics Inc
|
3.18 | 13.77M | 1.99M | -5.28M | -3.59M | -1.3727 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cyclerion Therapeutics Inc Stock (CYCN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-21 | Initiated | Truist | Buy |
| Sep-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-03-19 | Initiated | Credit Suisse | Neutral |
Cyclerion Therapeutics Inc Stock (CYCN) Latest News
Cyclerion Therapeutics, Inc. announced that it has received $200 million in funding - marketscreener.com
Cyclerion Therapeutics (CYCN) Hovers Near $3.00 as Low Volume Caps MovementDark Pool Volume - newsline.com
Cyclerion (NASDAQ: CYCN) to Merge with Korsana, $380M Pre-Closing Financing - Stock Titan
Cyclerion Therapeutics stock soars 350% on Korsana merger, $380 million financing - MSN
Cyclerion Therapeutics (CYCN) Edges Higher Amid Quiet TradingCash Flow Strong Stocks - The Legal Advocate
CYCN Q4 2025 Earnings: Narrowed Losses Exceed Expectations as Development Programs ProgressPre-Earnings Drift - The Legal Advocate
Cyclerion Therapeutics Company Profile & Introduction - Moomoo
Cyclerion Therapeutics (CYCN) Edges Higher as Shares Test Key Resistance LevelsRounding Bottom - The Legal Advocate
Cyclerion Shares to Watch With Deal in Focus as Markets Reopen - Bez Kabli
CYCN Q4 2025 Earnings: Narrowed Loss Beats Street Estimates, Shares ClimbAnnual Report - newsline.com
Cyclerion (CYCN) Delivers Q4 2025 Beat — EPS $-0.21 vs $-0.39 ExpectedTangible Book Value - newsline.com
Cyclerion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Korsana deal and cash crunch reshape Cyclerion (NASDAQ: CYCN) outlook - Stock Titan
TradingKey - TradingKey
CYCN News | CYCLERION THERAPEUTICS INC (NASDAQ:CYCN) - ChartMill
Why Cyclerion (CYCN) deserves a deeper look right now (-2.78%) 2026-05-07Insider Info - newser.com
FMR LLC holds 15.0% of Cyclerion Therapeutics (NASDAQ: CYCN) in Schedule 13G - Stock Titan
Are OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders? - Sahm
CYCN | Cyclerion Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
Cyclerion Therapeutics stock soars after strategic Medsteer collaboration By Investing.com - Investing.com Nigeria
Cyclerion Therapeutics 2024 10-K/A Amendment: Executive Compensation, Governance, and Equity Awards Overview - Minichart
Cyclerion Therapeutics (NASDAQ: CYCN) updates board, compensation and PIPE details - Stock Titan
CYCN stock is soaring 150% pre-market today — what is fueling the rally? - MSN
CYCN SEC FilingsCyclerion Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cyclerion Merges with Korsana to Develop Alzheimer Antibody Therapy - HarianBasis.co
Cyclerion Therapeutics (CYCN) Merges With Korsana Biosciences to Advance Alzheimer’s Pipeline - Insider Monkey
5 Unstoppable Stocks That Could Double Your Money - Insider Monkey
Is Cyclerion (CYCN) stock outperforming similar companies (Drifts Higher) 2026-04-18Open Stock Signal Network - Xã Thanh Hà
EDGAR Filing Documents for 0001193125-26-162177 - SEC.gov
Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement - Yahoo Finance
Published on: 2026-04-13 23:21:17 - baoquankhu1.vn
Guidance Update: Is Cyclerion Therapeutics Incs growth already priced inEarnings Recap Summary & Fast Entry Momentum Alerts - baoquankhu1.vn
Finance Watch: Replimune Cutting Jobs As FDA Rejects RP1 A Second Time - Citeline News & Insights
Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Shareholders? - Finviz
Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Sharehol - GuruFocus
Fed Watch: Is Cyclerion Therapeutics Incs growth already priced inQuarterly Earnings Summary & AI Optimized Trade Strategies - baoquankhu1.vn
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Cyclerion Therapeutics, Inc. (Nasdaq – CYCN), National Storage Affiliates (NYSENSA), Urgent.ly, Inc. (OTC MarketsULYX), UniFirst Corporation (NYSEU - ChartMill
12 Health Care Stocks Moving In Tuesday's After-Market Session - Sahm
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Rate Hike: Is Cyclerion Therapeutics Incs growth already priced in2026 Historical Comparison & Expert Approved Momentum Ideas - baoquankhu1.vn
Halper Sadeh LLC is Investigating Whether SLNO, FORA, MKC, CYCN are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Halper Sadeh LLC is Investigating Whether SLNO, FORA, MKC, CYCN are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Alzheimer’s company Korsana heads to NASDAQ via merger: Deals Report - BioCentury
Monday's session: gap up and gap down stocks - ChartMill
Penny stock CYCN surged more than 300% yesterday. Why, and should you chase the rally here? - MSN
CYCN PE Ratio & Valuation, Is CYCN Overvalued - Intellectia AI
CYCN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
If You Invested $1,000 in Cyclerion Therapeutics Inc (CYCN) - Stock Titan
Cyclerion Therapeutics Inc Stock (CYCN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):